TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03454022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DART
Description: A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choosing a Treatment for Kidney Failure
Description: This is an educational pamphlet published by the National Kidney Foundation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choosing a Treatment for Kidney Failure
Description: This is an educational pamphlet published by the National Kidney Foundation.
Study: NCT01811251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)
Study: NCT00878371

Intervention type: DRUG
Group type: OTHER
Intervention: morphine
Description: All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
Study: NCT01923129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin given 6 hours prior to catheter removal in the 24 hour group
Description: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
Study: NCT00822107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 50 mg one time
Study: NCT04480177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foot insole
Description: the subject was instructed to wear foot insole for 8 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: foot insole
Description: the subject was instructed to wear foot insole for 8 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short foot exercise
Description: the subject was instructed to perform exercise once a day 30 repetitions.
Study: NCT02287727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT01058096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
Study: NCT03603496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Tobacco Care Management (TTCM)
Description: PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eReferral to State Tobacco Quitline (QL)
Description: Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy
Description: Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
Study: NCT01014741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: 0.25mg IV ibutilide after PV isolation prior to CFE ablation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo after PV isolation prior to CFE ablation.
Study: NCT04319328

Intervention type: DRUG
Intervention: Cefazolin
Description: Non-interventional pharmacokinetic evaluation

Intervention type: DRUG
Intervention: Ceftazidime
Description: Non-interventional pharmacokinetic evaluation
Study: NCT04317274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good high cholesterol video
Description: The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good high cholesterol video
Description: The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor high cholesterol video
Description: The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor high cholesterol video
Description: The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good colon cancer screening video
Description: The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good colon cancer screening video
Description: The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor colon cancer screening video
Description: The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poor colon cancer screening video
Description: The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
Study: NCT03970187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure-based eye contact training in Virtual Reality (VR)
Description: The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking.
Study: NCT02486055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPM31510 Oral Nanosuspension 4%
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPM31510 Oral Nanosuspension 4%
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Study: NCT01358656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single bundle anterior cruciate ligament reconstruction
Description: The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith \& Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double bundle anterior cruciate ligament reconstruction
Description: The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
Study: NCT04793425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application (afterAMI)
Description: The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs.
Study: NCT03369964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emactuzumab
Description: In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle
Study: NCT04707898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Bond Universal
Description: Adhesive system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-Premio Bond
Description: Adhesive system
Study: NCT02556398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar Sleuth
Description: Educational module and use of smart phone app (Sugar Sleuth)
Study: NCT03732300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASSIP
Description: Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
Study: NCT03398577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
Study: NCT04051437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Description: During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
Study: NCT01889290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
Study: NCT02981680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Description: Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham-RIPC
Study: NCT00683033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief smoking cessation counseling
Description: For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation counseling
Description: For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
Study: NCT03202966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
Study: NCT01508728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOSENS orthosis
Description: with active vibration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ORTHOSENS orthosis
Description: with placebo vibration
Study: NCT03948828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NK cell therapy
Description: After conventional treatment, the patients were treated with autologous NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa combained with reverse addition therapy
Description: Postoperative patients were treated with GnRHa combined with reverse addition treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: GnRHa combained with reverse addition therapy
Description: Postoperative patients were treated with GnRHa combined with reverse addition treatment.
Study: NCT00674050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI) Inhalation Powder
Description: 3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol (Salbutamol)
Description: 2 puff= 200ug total dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: 2 puffs= 500ug total dose
Study: NCT04519385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethsone pulse therapy
Study: NCT00606086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-5005
Description: 40YU, subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GI-5005
Description: 40YU, subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon and Ribavirin
Description: Pegylated interefron is an injection and ribavirin is an oral tablet
Study: NCT02500628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg orally after baseline testing of heart rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg orally after baseline testing of heart rate
Study: NCT02342015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg/day for three months
Study: NCT00927095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous OC (EE/DROS)
Description: Continuous EE(20ug)+DROS(3mg) daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent OC (EE/DROS)
Description: Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily placebo
Study: NCT02274103

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BFST
Description: Family-based skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BFST
Description: Family-based skills training.
Study: NCT01471457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimo-San gel
Description: Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
Study: NCT04417478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planning
Description: Periodontal debridement was performed in all patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Periodontal debridement was performed in all patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Periodontal debridement was performed in all patients.
Study: NCT02474966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation (dTMS)
Description: Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation (dTMS)
Description: Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
Study: NCT02733666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable screw group
Description: Open reduction was performed and one absorbable screw was used for fixation in the experimental group
Study: NCT02480127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPELLE Endometrial injury
Description: The endometrial injury which is induced with pipelle.